0
     

Report Added
Report already added
Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Onychomycosis (Tinea Unguium) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline landscape.

Onychomycosis is a chronic fungal infection of the nails caused by dermatophytes. Symptoms include thickened nail that is difficult to cut, brittle or ragged nail, discolored or unsightly nail and pain of the finger or toe with ordinary activities. Treatment includes antifungal medications and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Onychomycosis (Tinea Unguium) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Onychomycosis (Tinea Unguium) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 1, 8, 2, 5, 1 and 3 respectively.

Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Onychomycosis (Tinea Unguium) (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Onychomycosis (Tinea Unguium) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Onychomycosis (Tinea Unguium) (Infectious Disease)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Onychomycosis (Tinea Unguium) (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Onychomycosis (Tinea Unguium) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Onychomycosis (Tinea Unguium) - Overview
Onychomycosis (Tinea Unguium) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Onychomycosis (Tinea Unguium) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Onychomycosis (Tinea Unguium) - Companies Involved in Therapeutics Development
Acea Biotech Inc
Almirall SA
Amtixbio Co Ltd
ASCIL Biopharm
Blueberry Therapeutics Ltd
CSA Biotechnologies LLC
DermBiont Inc
Exodos Life Sciences Limited Partnership
Hallux Inc
Hexima Ltd
Infextious Therapeutic
Kaken Pharmaceutical Co Ltd
Moberg Pharma AB
Mycovia Pharmaceuticals Inc
NAL Pharmaceuticals Ltd
Nektr Technologies Ltd
Novabiotics Ltd
Photonamic GmbH & Co KG
SaNOtize Research and Development Corp
TTY Biopharm Co Ltd
Turn Therapeutics Inc
Onychomycosis (Tinea Unguium) - Drug Profiles
A-31S - Drug Profile
Product Description
Mechanism Of Action
History of Events
aminolevulinic acid hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
ATB-1651 - Drug Profile
Product Description
Mechanism Of Action
BB-0305 - Drug Profile
Product Description
Mechanism Of Action
History of Events
benzalkonium chloride + polyhexanide - Drug Profile
Product Description
Mechanism Of Action
DBI-001 - Drug Profile
Product Description
Mechanism Of Action
efinaconazole - Drug Profile
Product Description
Mechanism Of Action
History of Events
ELS-160 - Drug Profile
Product Description
Mechanism Of Action
IFX-103 - Drug Profile
Product Description
Mechanism Of Action
KP-607 - Drug Profile
Product Description
Mechanism Of Action
NAL-3210 - Drug Profile
Product Description
Mechanism Of Action
NORS-0791 - Drug Profile
Product Description
Mechanism Of Action
NP-213 - Drug Profile
Product Description
Mechanism Of Action
History of Events
onymed - Drug Profile
Product Description
Mechanism Of Action
oteseconazole - Drug Profile
Product Description
Mechanism Of Action
History of Events
P-3058 - Drug Profile
Product Description
Mechanism Of Action
History of Events
pezadeftide - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Disrupt Cell Membrane for Onychomycosis - Drug Profile
Product Description
Mechanism Of Action
History of Events
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
terbinafine hydrochloride - Drug Profile
Product Description
Mechanism Of Action
History of Events
TTY-W - Drug Profile
Product Description
Mechanism Of Action
Onychomycosis (Tinea Unguium) - Dormant Projects
Onychomycosis (Tinea Unguium) - Discontinued Products
Onychomycosis (Tinea Unguium) - Product Development Milestones
Featured News & Press Releases
Jan 12, 2022: Hallux starts phase 2 clinical study of novel subungual gel for onychomycosis
Dec 23, 2021: The Medical Products Agency in Sweden will be reference member state for Moberg Pharma’s European registration application
Sep 22, 2021: Moberg Pharma receives approval from the EMA's Paediatric Committee
Aug 24, 2021: China patent for pezadeftide granted ACCESS CHINA Biotech Forum presentation investor webinar on 2 September 2021
Jul 26, 2021: Hexima: Completion of enrolment in phase IIb clinical trial
Jul 15, 2021: Hexima: Presentation of Phase I/IIa study data at American Podiatric Medical Association (APMA) and Investor Webinar
Jul 14, 2021: Hexima: Grant of European Patent over HXP124
Jun 10, 2021: Moberg Pharma: Phase 3-results for MOB-015 published in JAAD
May 20, 2021: Hexima announces INN designation for HXP124
May 12, 2021: Hexima : Grant of Australian patent over HXP124
Apr 26, 2021: Hexima to present at American Podiatric Medical Association annual conference
Mar 10, 2021: Acceptance of Clenafin/Jublia (efinaconazole) for regulatory review in China
Jan 07, 2021: Updated timeline to phase IIb results
Oct 14, 2020: Moberg Pharma intends to submit a registration application in Europe in 2021
Sep 14, 2020: Launch of Jublia, a treatment for tinea unguium, in Macau
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Onychomycosis (Tinea Unguium), 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Acea Biotech Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Almirall SA, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Amtixbio Co Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by ASCIL Biopharm, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Blueberry Therapeutics Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by CSA Biotechnologies LLC, 2022
Onychomycosis (Tinea Unguium) - Pipeline by DermBiont Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Exodos Life Sciences Limited Partnership, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Hallux Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Hexima Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Infextious Therapeutic, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Kaken Pharmaceutical Co Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Moberg Pharma AB, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Mycovia Pharmaceuticals Inc, 2022
Onychomycosis (Tinea Unguium) - Pipeline by NAL Pharmaceuticals Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Nektr Technologies Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Novabiotics Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Photonamic GmbH & Co KG, 2022
Onychomycosis (Tinea Unguium) - Pipeline by SaNOtize Research and Development Corp, 2022
Onychomycosis (Tinea Unguium) - Pipeline by TTY Biopharm Co Ltd, 2022
Onychomycosis (Tinea Unguium) - Pipeline by Turn Therapeutics Inc, 2022
Onychomycosis (Tinea Unguium) - Dormant Projects, 2022
Onychomycosis (Tinea Unguium) - Dormant Projects, 2022 (Contd..1)
Onychomycosis (Tinea Unguium) - Discontinued Products, 2022

List of Figures
Number of Products under Development for Onychomycosis (Tinea Unguium), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

Report Title: Onychomycosis (Tinea Unguium) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW